[EN] 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS DE 6-1H-IMIDAZO-QUINAZOLINE ET QUINOLÉINES, NOUVEAUX INHIBITEURS DE MAO ET LIGANDS DES RÉCEPTEURS D'IMIDAZOLINES
申请人:ROTTAPHARM SPA
公开号:WO2009152868A1
公开(公告)日:2009-12-23
The present invention is directed to 6-(1H-imidazo-1-yl)-2-aryl and 2-heteroaryl quinazoline and quinolines derivatives, compounds of formula (I), their pharmaceutical acceptable salts and solvates and corresponding pharmaceutical compositions, that acts as Monoamine Oxidase (MAO) inhibitors and Imidazoline Receptor ligands: wherein: X is independently selected from -CH group or a nitrogen atom (-N), W is independently selected from an aryl group, an heteroaryl group, or a benzocondensed heteroaryl group such as 1,3-benzodioxole, benzofuran, 2,3-dihydrobenzofuran, benzothiophene, 2,3-dihydrobenzothiophene, indole, 2,3-dihydroindole, benzimidazole, benzoxazole, benzothiazole, 2H-3,4-dihydrobenzopyran, [l,4]-benzodioxine, 2,3-dihydro-[1,4]-benzodioxine (1,4-benzodioxan). R1 is independently selected from hydrogen (-H), C1-C4alkyl, hydroxymethyl (-CH2OH), aminomethyl (-CH2NH2), alkylaminomethyl [CH2NH(R2)], or di-alkylaminomethyl [CH2N(R2)2], trifiuoromethyl (-CF3). Compounds of formula (I) elicited a pharmacological profile suitable for the clinical treatment of depression and related disorders, Parkinson disease, drug abuse, and morphine tolerance and dependence.
本发明涉及6-(
1H-咪唑-1-基)-2-芳基和2-杂芳基
喹唑啉和
喹啉衍
生物,这些衍
生物的
化学式为(I),以及它们的药用盐和溶剂化物以及相应的药物组合物,作为单胺氧化酶(MAO)
抑制剂和
咪唑啉受体
配体:其中:X独立地选自-CH基团或氮原子(-N),W独立地选自芳基团、杂芳基团或如1,3-苯并二氧杂
环戊烷、
苯并呋喃、
2,3-二氢苯并呋喃、
苯并噻吩、2,3-二氢
苯并噻吩、
吲哚、2,3-二氢
吲哚、
苯并咪唑、苯并
噁唑、
苯并噻唑、2H-3,4-二氢苯并
吡喃、[1,4]-苯并二氧杂
环戊烷、2,3-二氢-[1,4]-苯并二氧杂
环戊烷(1,4-苯并二氧杂
环戊烷)。R1独立地选自氢(-H)、C1-C4烷基、羟甲基(-CH2OH)、
氨基甲基(-CH2NH2)、烷基
氨甲基[CH2NH(R2)]或二烷基
氨甲基[CH2N(R2)2]、三
氟甲基(-
CF3)。
化学式(I)的化合物展现出适合于临床治疗抑郁症和相关障碍、帕
金森病、药物滥用以及
吗啡耐受性和依赖性的药理特性。